Pasar al contenido principal

SUCCINATO DESHIDROGENASA Y ENFERMEDAD HUMANA: DESCUBRIMIENTOS INESPERADOS SOBRE UNA ENZIMA BIEN CONOCIDA

PID2023-150506OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE VALLADOLID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Succinate Dehydrogenase and Human Disease: Novel Insights into a Well-Known Enzyme

  • Esteban-Amo, María J.
  • Jiménez-Cuadrado, Patricia
  • Serrano-Lorenzo, Pablo
  • Fuente, Miguel A. de la
  • Simarro-Grande, María
Succinate dehydrogenase (also known as complex II) plays a dual role in respiration by catalyzing the oxidation of succinate to fumarate in the tricarboxylic acid (TCA) cycle and transferring electrons from succinate to ubiquinone in the mitochondrial electron transport chain (ETC). Owing to the privileged position of SDH/CII, its dysfunction leads to TCA cycle arrest and altered respiration. This review aims to elucidate the widely documented profound metabolic effects of SDH/CII deficiency, along with the newly unveiled survival mechanisms in SDH/CII-deficient cells. Such an understanding reveals exploitable vulnerabilities for strategic targeting, which is crucial for the development of novel and more precise therapies for primary mitochondrial diseases, as well as for familial and sporadic cancers associated with SDH/CII mutations., The APC was funded by Agencia Estatal de Investigación, Grant Number PID2023-150506OB-I00., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Identification of a novel transcript of mouse Sdha

  • Esteban-Amo, María J.
  • Tellería, Amaia
  • Gobelli, Dino
  • Serrano-Lorenzo, Pablo
  • Tellería, Juan José
  • Pérez-García, M. Teresa
  • Kozlowski, Piotr
  • Fuente, Miguel A. de la
  • Simarro-Grande, María
[Objective] This study aimed to identify novel isoforms of mouse succinate dehydrogenase complex flavoprotein subunit A (Sdha) arising from internal exon skipping, analogous to the process observed in human ortholog SDHA., [Results] We identified a novel isoform, designated Δ3-10, which lacked the final 104 nucleotides of exon 3 and all of exons 4 through 10, yet did not alter the reading frame. The Δ3-10 Sdha cDNA was cloned into expression vectors, and overexpression resulted in a protein localized to the mitochondria. However, the endogenous Δ3-10 Sdha protein was not detected with the available antibodies., Agencia Estatal de Investigación, Grant Number PID2023-150506OB-I00; Consejería de Educación, Junta de Castilla y León, Grant Number VA172P20; Consejería de Sanidad, Junta de Castilla y León, Grant Number GRS 2201/A/2020; Programa Estratégico Instituto de Biomedicina y Genética Molecular (IBGM), Junta de Castilla y León, Award Number CCVC8485., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Impact of compound heterozygous SDHA variants on mitochondrial function in pediatric with neurological disease

  • Garrido-Moraga, Rocío
  • Serrano-Lorenzo, Pablo
  • Esteban-Amo, María J.
  • Bellusci, Marcello
  • de la Fuente, Miguel Á.
  • Arenas, Joaquín
  • González-Quintana, Adrián
  • Ugalde, Cristina
  • Simarro, María
  • Martín, Miguel A.
This study examines two rare compound heterozygous missense variants in the SDHA gene, c.1535G > A (p.R512Q) and c.1753C > T (p.R585W), identified in a pediatric patient presenting with neurological manifestations, including epilepsy, developmental delay, and optic atrophy. The SDHA gene encodes a key component of succinate dehydrogenase (SDH), an essential enzyme complex at the intersection of two fundamental metabolic pathways: the Krebs cycle, and the mitochondrial respiratory chain (MRC). Patient-derived fibroblasts were used to evaluate the impact of the mutations on SDH activity and MRC assembly and function. The analysis revealed significant decreases in SDH activity and subunit levels, as well as impaired assembly. Additionally, complex I (CI) activity and CI-containing supercomplexes formation were also impaired, indicating more widespread mitochondrial dysfunction. Unexpectedly, basal and maximal respiration rates remained unchanged, though spare respiratory capacity was significantly reduced. These findings demonstrate the deleterious effects of the c.1535G > A and c.1753C > T variants, which had previously been associated with primary mitochondrial disorder (PMD) and tumors but had not been functionally validated until now, This research was funded by the Instituto de Salud Carlos III, (ISCIII) and the Ministerio de Ciencia e Innovación (Madrid, Spain; co-funded by European Regional Development Fund “A way to make Europe”), grant number PI21/00381 to M.A.M. This work was also partially funded by the Agencia Estatal de Investigación, Grant Number PID2023- 150506OB-I00., Peer reviewed, Modelo experimental alternativo-NAM, in vitro - Tipos celulares - líneas celulares primarias
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pleiotropic impact of the loss of complex II in the organization of the respiratory chain and the mitochondrial ultrastructure

  • Esteban-Amo, María J.
  • Acín-Pérez, Rebeca
  • Fernandez-Martinez, Silvia
  • Calvo, Enrique
  • Vázquez, Jesús
  • Enríquez, José Antonio
  • Fuente, Miguel A. de la
  • Simarro-Grande, María
Succinate dehydrogenase (SDH, mitochondrial complex II) connects the tricarboxylic acid cycle and oxidative phosphorylation, and its dysfunction is associated with a broad spectrum of human diseases. It comprises a catalytic SDHA subunit and the electron-transferring SDHB subunit, which transfers electrons to the membrane-embedded SDHC/SDHD module where ubiquinone reduction occurs. Recessive defects in SDHA cause early-onset mitochondrial and neurodegenerative disorders, whereas heterozygous mutations in SDHB predispose to tumor development. A distinctive feature of SDHB deficiency is the accumulation of a stable assembly intermediate (CII-low) containing flavinated SDHA, whose functional relevance remains largely unexplored. Despite extensive characterization of SDH-related metabolic alterations, its direct impact on mitochondrial respiration and respiratory chain architecture has remained insufficiently defined. To address this critical gap, we established human cellular models deficient in either SDHA or SDHB, enabling discrimination between complete loss of complex II and conditions marked by CII-low accumulation. We found that CII-low lacked uncoupled activity despite containing flavinated SDHA. In both models, the loss of complex II activity caused severe impairment of mitochondrial respiration and ATP production. These changes were accompanied by marked remodeling of the respiratory chain, with complex I being the most consistently affected complex, as shown by BN-PAGE and proteomic analyses. At the organelle level, SDH deficiency induced mitochondrial abnormalities, including reduced cristae density. The similarity between the two knockout models indicates that the presence of CII-low does not make a major contribution to the observed phenotypes. These findings indicate that SDH deficiency contributes to disease through disruption of mitochondrial respiratory chain organization and ultrastructure., MS and MAF acknowledge grant PID2023-150506OB-I00 funded by MICIU and VA172P20 funded by Junta de Castilla y León. JV acknowledges grants PID2021-122348NB-I00 and PID2024-155650NB-I00 funded by MICIU and by “ERDF A way of making Europe”, PLEC2022-009298, PLEC2022-009235 and EQC2021-007053-P funded by MICIU and by “European Union NextGenerationEU/ PRTR”, S2022/BMD-7333-CM (INMUNOVAR-CM) funded by Comunidad de Madrid and LCF/PR/HR22/52420019 funded by ‘la Caixa’ Foundation. MJEA was supported by a predoctoral contract from the University of Valladolid., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The KEAP1/NRF2 axis controls LPS-induced oxidative stress, inflammasome activation and caspase-1 activity in human endothelial cells

  • Montero-Jodra, Alba
  • Esteban-Amo, María J.
  • Fernandez-Martinez, Silvia
  • García Martínez, César
  • Fuente, Miguel A. de la
  • García-Concejo, Adrián
  • Martín-Fernández, Marta
  • Tamayo, Eduardo
  • Simarro-Grande, María
Endothelial cells play a critical role in the inflammatory response during sepsis, however, their metabolic adaptations to inflammatory stimuli remain much less characterized compared to immune cells. Here, we demonstrate that Human Umbilical Vein Endothelial Cells (HUVECs) do not undergo the metabolic and respiratory rewiring typically observed in macrophages following lipopolysaccharide (LPS) stimulation, a common model of inflammation during sepsis. A key metabolite in LPS-activated macrophages is itaconate, which is known for its anti-inflammatory properties. Although HUVECs do not naturally produce itaconate, we explored whether exogenous administration of the cell-permeable derivative 4-octyl itaconate (4-OI) could modulate their response to LPS. Remarkably, 4-OI treatment significantly reduced mitochondrial reactive oxygen species (mitoROS) levels in LPS-treated HUVECs, restoring them to baseline levels. This antioxidant effect was accompanied by a pronounced decrease in inflammasome activation, including suppression of ASC speck formation and caspase-1 activation. These findings suggest that 4-OI could protect endothelial cells from inflammation during sepsis in a manner similar to its role in macrophages. Mechanistically, 4-OI acts through the KEAP1/NRF2 antioxidant pathway. Silencing of KEAP1, the direct molecular target of 4-OI, resulted in a pronounced upregulation of NRF2 target genes, particularly HMOX1, with modest effects on NQO1 and no change in GCLC. NRF2 knockdown decreased HMOX1 expression and blunted 4-OI’s effects, although some residual induction persisted. Further confirming the importance of this pathway, KEAP1 silencing itself suppressed LPS-induced mitoROS, ASC speck formation, and caspase-1 activation, mimicking 4-OI treatment. Taken together, these results demonstrate that 4-OI protects endothelial cells from LPS-induced oxidative stress and inflammation primarily via the KEAP1/NRF2 axis., Ministerio de Ciencia, Innovación y Universidades (PID2023-150506OB-I00) (AMJ,MJEA,MAF,MS) Instituto de Salud Carlos III (PI21/00917); Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC CB21/13/00051) Instituto de Salud Carlos III. (AGC,MMF,ETG) Ministerio de Ciencia, Innovación y Universidades (PTA2021-021155-I) (SFM) Consejería de Educación de la Junta de Castilla y León (IR2020-1-UVA05) (SFM), Peer reviewed